Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2014 · 10-Q
Revenue$8.09M$8.09M−21.1% vs Q1 2013 Net Income$286.32K$286.32K−66.5% vs Q1 2013 EPS Diluted$0.02$0.02−60.0% vs Q1 2013 Operating Income$408,051−69.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived$952,812−40.8% Margins · derivedOperating margin5.0%−7.9 pt vs Q1 2013
Net margin3.5%−4.8 pt vs Q1 2013
ended Mar 31, 2014 · filed May 12, 2014 · 42 d after period end